US Stock MarketDetailed Quotes
ELEV Elevation Oncology
- 0.523
- -0.013-2.50%
Close Nov 4 16:00 ET
- 0.542
- +0.020+3.73%
Post 17:57 ET
30.89MMarket Cap-768P/E (TTM)
0.556High0.522Low658.55KVolume0.536Open0.536Pre Close353.30KTurnover1.60%Turnover RatioLossP/E (Static)59.11MShares5.83052wk High0.38P/B21.46MFloat Cap0.36352wk Low--Dividend TTM41.05MShs Float16.220Historical High--Div YieldTTM6.25%Amplitude0.363Historical Low0.536Avg Price1Lot Size
Elevation Oncology Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 40.59%-8.21M | 43.11%-9.58M | 34.28%-56.18M | 31.76%-12.18M | 69.77%-13.36M | -46.50%-13.81M | -20.02%-16.83M | -183.37%-85.48M | -100.24%-17.85M | -459.00%-44.18M |
| Net income from continuing operations | -3.47%-10.46M | 37.24%-10.71M | 51.93%-45.7M | 58.52%-7.9M | 72.61%-10.64M | 49.26%-10.11M | 1.25%-17.06M | -196.76%-95.08M | -97.90%-19.04M | -216.60%-38.84M |
| Operating gains losses | --0 | --942K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -60.00%4K | 0.00%10K | 44.44%39K | 0.00%10K | 12.50%9K | 100.00%10K | 150.00%10K | 50.00%27K | 100.00%10K | 166.67%8K |
| Other non cash items | -37.79%107K | -2.42%161K | 146.32%702K | 10.78%185K | --180K | --172K | --165K | --285K | --167K | ---- |
| Change In working capital | 131.38%1.45M | 51.91%-605K | -317.65%-13.69M | -1,380.84%-4.28M | 43.76%-3.55M | -147.67%-4.61M | -148.25%-1.26M | 2,122.61%6.29M | 2,285.71%334K | -270.52%-6.31M |
| -Change in prepaid assets | 94.53%996K | 36.07%1.23M | -251.31%-2.14M | -215.89%-815K | -18.40%-2.74M | -48.95%512K | -6.15%901K | 64.58%-610K | -348.08%-258K | -1.58%-2.32M |
| -Change in payables and accrued expense | 108.77%449K | 15.19%-1.83M | -267.35%-11.55M | -684.97%-3.46M | 79.78%-808K | -159.11%-5.12M | -231.09%-2.16M | 244.14%6.9M | 757.78%592K | -166.82%-4M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 40.59%-8.21M | 43.11%-9.58M | 34.28%-56.18M | 31.76%-12.18M | 69.77%-13.36M | -46.50%-13.81M | -20.02%-16.83M | -183.37%-85.48M | -100.24%-17.85M | -459.00%-44.18M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -328.24%-37.66M | -22.18%20.7M | 126.00%11.54M | -41.33%6.56M | -385.18%-38.12M | 59.79%16.5M | 133.56%26.6M | -44.4M | 11.18M | 13.37M |
| Net PPE purchase and sale | ---- | ---- | --0 | --0 | ---- | ---- | ---- | ---86K | --0 | ---- |
| Net investment purchase and sale | -328.24%-37.66M | -22.18%20.7M | 126.05%11.54M | -41.33%6.56M | -383.36%-38.12M | 59.79%16.5M | 133.56%26.6M | ---44.31M | --11.18M | --13.45M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -328.24%-37.66M | -22.18%20.7M | 126.00%11.54M | -41.33%6.56M | -385.18%-38.12M | 59.79%16.5M | 133.56%26.6M | ---44.4M | --11.18M | --13.37M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -69.24%14.68M | 13,904.63%30.25M | 62.55%47.98M | 50.00%-2K | -99.91%27K | 191,036.00%47.73M | 1,036.84%216K | -69.59%29.51M | -4K | 480.61%29.52M |
| Net issuance payments of debt | ---- | ---- | --0 | --0 | ---- | ---- | ---- | --30M | --0 | ---- |
| Net common stock issuance | -68.74%14.54M | 247,016.67%29.63M | 132,897.14%46.48M | 50.00%-2K | 50.00%-3K | 186,084.00%46.5M | ---12K | -100.04%-35K | ---4K | -100.12%-6K |
| Proceeds from stock option exercised by employees | -86.51%167K | 237.72%770K | 7,773.68%1.5M | --0 | --30K | --1.24M | 1,100.00%228K | --19K | --0 | --0 |
| Net other financing activities | ---20K | ---150K | ---- | ---- | ---- | ---- | ---- | -4,172.73%-470K | --0 | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -69.24%14.68M | 13,904.63%30.25M | 62.55%47.98M | 50.00%-2K | -99.91%27K | 191,036.00%47.73M | 1,036.84%216K | -69.59%29.51M | ---4K | 480.61%29.52M |
| Net cash flow | ||||||||||
| Beginning cash position | 62.12%90.63M | 7.27%49.26M | -68.61%45.92M | 4.35%54.88M | 97.33%106.33M | 5.46%55.9M | -68.61%45.92M | 84.24%146.28M | -66.11%52.59M | -65.90%53.88M |
| Current changes in cash | -161.84%-31.18M | 314.37%41.38M | 103.33%3.34M | 15.72%-5.62M | -3,878.89%-51.45M | 5,669.22%50.42M | 110.70%9.99M | -250.06%-100.37M | 25.15%-6.67M | 54.13%-1.29M |
| End cash Position | -44.09%59.45M | 62.12%90.63M | 7.27%49.26M | 7.27%49.26M | 4.35%54.88M | 97.33%106.33M | 5.46%55.9M | -68.61%45.92M | -68.61%45.92M | -66.11%52.59M |
| Free cash flow | 40.59%-8.21M | 43.11%-9.58M | 34.35%-56.18M | 31.76%-12.18M | 69.83%-13.36M | -46.50%-13.81M | -20.02%-16.83M | -183.65%-85.57M | -100.24%-17.85M | -460.08%-44.27M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data